Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer-Reference-Cited by-同舟云学术

Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer

Published:2024-08-28 Issue: Volume: Page:
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Sudo Kentaro,Nakamura Yoshiaki^ORCID,Ueno Makoto,Furukawa Masayuki,Mizuno Nobumasa^ORCID,Kawamoto Yasuyuki,Okano Naohiro^ORCID,Umemoto Kumiko,Asagi Akinori,Ozaka Masato,Ohtsubo Koushiro,Shimizu Satoshi,Matsuhashi Nobuhisa,Itoh Shinji,Matsumoto Toshihiko,Satoh Taroh,Okuyama Hiroyuki,Goto Masahiro,Hasegawa Hiroko,Yamamoto Yoshiyuki,Odegaard Justin I.,Bando Hideaki,Yoshino Takayuki^ORCID,Ikeda Masafumi^ORCID,Morizane Chigusa

Funder

SCRUM-Japan Fund

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02834-0.pdf

Reference39 articles.

1. Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39:2617–31.

2. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16:1397–402.

3. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132–8.

4. Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, et al. Should platinum-based chemotherapy be preferred for germline Breast Cancer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev. 2019;80:101895.

5. Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, et al. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open. 2021;6:100238.